AIM ImmunoTech Inc. Stock News

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) rose 149.3% to $1.56 in pre-market trading after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phas

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 92.9% to $0.2295 in pre-market trading. Allena Pharmaceuticals said it previously entered into at market issuance sales agreement with B. Ril

Gainers Kezar Life Sciences, Inc. (NASDAQ: KZR) rose 78% to $10.29 in pre-market trading after the company reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomi

Company enters into a lease agreement with the state-supported New Jersey Bioscience Center at North Brunswick, one of the nation’s leading business incubators dedicated to life sciences and biotech

AIM ImmunoTech Inc (NYSE:AIM) announced that it has entered into a lease agreement with the New Jersey Economic Development Authority for a 5,210 square foot research and development (R&D) facility at

专利组合的进一步扩大支持了公司在荷兰的各种Ampligen研究项目，这些项目研究多种类型的癌症和病毒疾病，包括COVID-19 专利组合的进一步扩大支持了公

Verdere uitbreiding van de octrooiportefeuille ondersteunt het uitgebreide Ampligen-onderzoeksprogramma van het bedrijf voor meerdere soorten kankers en virusziekten, waaronder COVID-19 in Nederland V

Further expansion of patent portfolio supports of the Company’s extensive Ampligen research program across multiple types of cancers and viral diseases, including COVID-19 in the Netherlands Further

AIM ImmunoTech Inc (NYSE:AIM) revealed that the Netherlands Patent Office (Octrooicentrum Nederland) has issued Patent No 2027383 - a utility patent - covering Ampligen (rintatolimod) and other dsRNA

AIM ImmunoTech Inc (NYSE:AIM) has announced that it is working towards filing an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for its long COVID investigat

- First quarter marked by peer-reviewed journal and abstract publications showcasing statistically significant efficacy data of Ampligen in late-stage pancreatic cancer; results also showcased continu

OCALA, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeut

Ampligen has demonstrated in pre-clinical and now human clinical studies a potential to enhance efficacy of PD-1 and/or PD-L1 checkpoint inhibitors

AIM ImmunoTech Inc (NYSE:AIM) has provided a summary of positive clinical data supporting the synergistic potential of its flagship drug Ampligen (rintatolimod) with checkpoint blockade therapies. I

- Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer